Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
52-week range
$75.68 – $94.33
99% from low
Exchange
ARCX
ETF
No company description on file.
No one on the platform currently holds AVDE.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 25,900 | $2.2M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-06-09 | $1.1657 | 2026-06-11 |
| 2026-03-10 | $0.0972 | 2026-03-12 |
| 2025-12-16 | $0.9433 | 2025-12-18 |
| 2025-06-24 | $1.2479 | 2025-06-26 |
| 2024-12-17 | $0.8501 | 2024-12-19 |
| 2024-06-24 | $1.1718 | 2024-06-26 |
| 2023-12-18 | $0.7718 | 2023-12-21 |
No one on the platform has traded AVDE yet.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| AVDEAvantis International Equity ETF | $94.15 | +0.12% | $17.8B | — |
| AVDVAvantis International Small Cap Value ETF | $110.41 | +0.12% | $20.0B | — |
| AVUSAvantis U.S. Equity ETF | $132.31 | +0.58% | $14.3B | — |
| DFAUDimensional - US Core Equity Market ETF | $53.80 | +0.51% | $12.8B | — |
| DFAXDimensional World ex U.S. Core Equity 2 ETF | $38.12 | +0.13% | $12.4B | — |
| DFICDimensional - International Core Equity 2 ETF | $39.25 | +0.06% | $14.7B | — |
| DUHPDimensional - US High Profitability ETF | $42.81 | +0.67% | $12.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
NVO Stock Drops 6% Despite Raised Guidance As Investors Worry About Injectable GLP-1 Sales Future $NVO $AVDE $PPH https://stocktwits.com/news/equity/markets/nvo-stock-drops-6-despite-raised-guidance-as-investors-worry-about-injectable-glp-1-sales-future/cZo5Hg0RJ4i
View on StockTwits ↗NVO Stock Ends Three-Month Winning Streak As Novo Nordisk’s Key Heart Drug Flops, Competition Goes To Court $NVO $AVDE $PPH https://stocktwits.com/news/equity/markets/nvo-stock-ends-three-month-winning-streak-novo-nordisk-s-key-heart-drug-flops-competition-goes-to-court/cZ8xiBeRJ5P
View on StockTwits ↗🌍 As AI and chip stocks stumble, investors are looking beyond U.S. tech. $VOO is down about 0.7% over the past month as AI worries deepen. 📊 Global diversification ideas include $AVDE $FNDF, value ETFs $EFV, and dividend ETFs $IDV. 🔗 Could international ETFs outperform VOO if AI-driven volatility persists? Read more here 👇 https://www.zacks.com/stock/news/2963563/global-etfs-to-diversify-as-tech-weakness-weighs-on-markets?_gl=1%2Ay96eec%2A_up%2AMQ..%2A_ga%2AMTA0NDc2NDE4My4xNzg1NDg0OTI0%2A_ga_MXXMZ1PBF7%2AczE3ODU0ODQ5MjQkbzEkZzAkdDE3ODU0ODQ5MjQkajYwJGwwJGg2MDcwNzI1OTc.&cid=sm-stocktwits-0-2963563-oc-39060&ADID=SYND_STOCKTWITS_TWEET_0_2963563_OC_39060
View on StockTwits ↗NVO Stock Jumps 3% As EU Approves Oral Wegovy Pill — Retail Notes LLY Is ‘Clearly Behind’ Its Danish Counterpart $NVO $PVAL $AVDE $LLY https://stocktwits.com/news/equity/markets/nvo-stock-jumps-3-as-eu-approves-oral-wegovy-pill-retail-notes-lly-is-clearly-behind-its-danish-counterpart/cZZPaw9R7r9
View on StockTwits ↗$QQQ $QLD $AVDE also took some profits from international yesterday. Overall tactical $$ will come in handy and imo sooner than later as this market does its spinning top candle and most people don’t realize we actually have bearish divergences on indices
View on StockTwits ↗AZN Stock Rise As Wall Street Dismisses FDA Committee’s Rejection Of Breast Cancer Drug $AZN $PVAL $AVDE https://stocktwits.com/news/equity/markets/azn-stock-rise-as-wall-street-dismisses-fda-commitees-rejection-of-breast-cancer-drug/cZBMnogReIf
View on StockTwits ↗BP Stock Jumps Over 3% Premarket: US-Iran War Drives Best Quarter In Years $BP $DFIV $AVDE https://stocktwits.com/news/equity/markets/bp-stock-jumps-premarket-us-iran-war-drives-best-quarter-in-years/cZB8oU3Re5j
View on StockTwits ↗GSK Reportedly Pulls Application For Drug Touted By Trump As Potential Treatment For Autism $GSK $AVDE $FENI https://stocktwits.com/news/equity/markets/gsk-reportedly-pulls-application-for-drug-touted-by-trump-as-potential-treatment-for-autism/cZJWiLwRIs1
View on StockTwits ↗Novo Nordisk Launches Higher Dose Of Wegovy Injection Across US — Retail Thinks Stock Is ‘Terribly Undervalued’ $NVO $PVAL $AVDE https://stocktwits.com/news/equity/markets/novo-nordisk-launches-higher-dose-of-wegovy-injection-across-us/cZJJyAuRIpU
View on StockTwits ↗Novo Nordisk-Hims Deal Turns Wall Street Bullish — BMO Sees Relief From Commercial Headwinds, BofA Upgrades HIMS Stock $NVO $HIMS $PPH $PVAL $AVDE https://stocktwits.com/news/equity/markets/novo-nordisk-hims-deal-turns-wall-street-bullish-hims-stock-upgrades/cZdos7IRI7d
View on StockTwits ↗HIMS Stock Soars After Novo Nordisk Drops Patent Infringement Lawsuit, Opens Access To Ozempic, Wegovy $HIMS $NVO $PPH $PVAL $AVDE https://stocktwits.com/news/equity/markets/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk
View on StockTwits ↗Why Is NVO Stock Falling Pre-Market Today? $NVO $PPH $PVAL $AVDE $FTHI https://stocktwits.com/news/equity/markets/why-is-nvo-stock-falling-pre-market-today/cZRtZlKR4UC
View on StockTwits ↗Novo Nordisk Reportedly Eyes Launching Wegovy In Vials To Compete With Rival Eli Lilly $NVO $PVAL $AVDE https://stocktwits.com/news/equity/markets/novo-nordisk-reportedly-eyes-launching-wegovy-in-vials/cZb6rpcR4A0
View on StockTwits ↗$AVDE Current Stock Price: $90.68 Contracts to trade: $85.0 AVDE Feb 20 2026 Call Entry: $4.00 Exit: $6.47 ROI: 62% Hold ~22 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.